Jupiter Hospitals Q1 FY27 Revenue at ₹411 Crores

Total Income: Stood at ₹411 crores.
EBITDA: ₹79.3 crores, resulting in an EBITDA Margin of 19.3%.
Profit After Tax (PAT): ₹37.5 crores.
Key Operational Metrics:
Average Revenue Per Occupied Bed (ARPOB): ₹73,500.
Average Length of Stay (ALOS): 3.76 days.
Average Occupancy Rate: 59.6% for the quarter, considering the dilution from the expanded bed base at the new Dombivli hospital.

The Dombivli hospital completed its first full quarter of operations in Q1 FY27.
It contributed an EBITDA drag of ₹9.5 crores for the quarter, which was stated to be in line with management's anticipation.
Current occupancy is estimated to be around 25-30%.
Fixed costs are estimated to be approximately ₹6-7 crores per month.
Doctor hiring is an ongoing process and is expected to continue for the next couple of years as sub-specialties are added.
Guidance Reiterated: Management expects an operational EBITDA loss of ₹2-3 crores per month for Dombivli and maintains its previous guidance for the unit to achieve EBITDA breakeven in 1.5 to 2 years.
Formal insurance empanelment processes are pending, which is seen as a friction point for patient intake. Once completed, this is expected to improve occupancy.
The oncology department, including radiation and LINAC services, is yet to be fully launched and is expected by the end of the calendar year.

Indore Unit: Reported EBITDA margins of ~12%. The lower margin was attributed to higher HR-related costs from new team and doctor hires in anticipation of growth for the rest of the year and a forthcoming expansion. The cost impact was estimated to be a "couple of crores." Current occupancy is around 50%.
Thane and Pune Units: Both were described as having similar mature operating profiles. Management noted that Q1 and Q3 are traditionally weaker quarters, while Q2 and Q4 are stronger.
Pune Growth Outlook: Revenue growth is expected to plateau or slow down as the unit has reached mid-60% occupancy, with a ceiling of around 75%.

The company recently acquired an IV fluids manufacturing plant for approximately ₹35-40 crores, including infrastructure.
This is positioned as a backward integration move for the company's pharmacy subsidiary, aimed at cost management and margin improvement.
Management explicitly stated this is not an entry into the pharma business but a strategic initiative for its existing hospital operations, given a line of sight to 3,000 beds across its network.
The capital outlay is considered insignificant compared to the planned hospital capex.

The company is currently in a roughly net debt-zero position, with approximately ₹500 crores of gross debt offset by ₹500 crores of cash on hand.
The increase in finance cost noted in the quarter was attributed to this higher debt level for ongoing capex.
The board has set a debt ceiling of 3x EBITDA.
Management expects internal accruals and existing cash to fund the current capex cycle for the next few years, with potential debt needed only towards the end of the cycle.
A clarification was provided on a recent filing about pledged shares: the increase was erroneously reported due to a 5x stock split, and the actual pledge amount has not changed. The pledge is by a non-promoter entity.

ARPOB Growth: For mature units, growth is expected to be in line with inflation. For newer units, growth is expected to be higher than inflation for the first few years due to case mix improvement (shifting from secondary to more tertiary and quaternary procedures).
Expansion Strategy: The company's strategy is to add new capacity (capex) once operational occupancy reaches about 60% of installed beds. This expansion will cause occupancy to drop to around 40%, potentially compressing margins but not resulting in EBITDA losses. This cycle repeats for future growth.
Future Projects: The three other upcoming hospital projects are reported to be on track. The management's focus for the next 5 years is on executing these projects in Western India, citing a strong demand-supply gap in organized healthcare.